Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 29, 2023
Space is almost too glamorous for its own good. This is understandable; for most of human existence, the nighttime sky has been unreachable, mysterious, yet strangely helpful (especially to those navigating or measuring time by the stars). Like the first ships to cross an ocean, early satellites wer...
Blog Post
March 07, 2023
The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...
Blog Post
March 02, 2023
To kick off Season 2 of Lagos to Mombasa, Gyude reflects on the intricacies of climate change and development in Africa and explores how space-based technologies can help. Temidayo Oniosun of Space in Africa and Rose Croshier from CGD join Gyude to discuss the intersections of space technology with ...
Blog Post
March 01, 2023
Last week I was just thinking about writing a blog about a new economics working paper, when I got access to the new Bing AI chatbot, trailed as yet another improvement on ChatGPT and with up to date internet access. It turns out Bing can write a very passable blog summary of a working paper recentl...
Blog Post
January 25, 2023
Last month, the Center for Global Development (CGD), the White House Office of Science and Technology Policy, and the Office of Management and Budget co-hosted an Evidence Forum as part of the White House Year of Evidence for Action, featuring USAID Administer Samantha Power. The event celebrated pr...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.